Modera Wealth Management LLC Cuts Stock Holdings in Eli Lilly and Company $LLY

Modera Wealth Management LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.1% in the second quarter, Holdings Channel.com reports. The fund owned 49,681 shares of the company’s stock after selling 533 shares during the quarter. Modera Wealth Management LLC’s holdings in Eli Lilly and Company were worth $38,728,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Twin Capital Management Inc. boosted its stake in Eli Lilly and Company by 8.0% during the 2nd quarter. Twin Capital Management Inc. now owns 19,376 shares of the company’s stock worth $15,104,000 after purchasing an additional 1,429 shares during the last quarter. Souders Financial Advisors lifted its stake in shares of Eli Lilly and Company by 2.4% in the second quarter. Souders Financial Advisors now owns 2,959 shares of the company’s stock worth $2,307,000 after buying an additional 69 shares in the last quarter. Achmea Investment Management B.V. boosted its position in Eli Lilly and Company by 1.1% during the second quarter. Achmea Investment Management B.V. now owns 64,533 shares of the company’s stock worth $50,305,000 after acquiring an additional 703 shares during the last quarter. HORAN Wealth LLC purchased a new stake in Eli Lilly and Company during the 2nd quarter valued at about $624,000. Finally, SouthState Corp grew its stake in Eli Lilly and Company by 10.3% during the 2nd quarter. SouthState Corp now owns 12,486 shares of the company’s stock valued at $9,733,000 after acquiring an additional 1,165 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Gabrielle Sulzberger bought 117 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $641.18 per share, with a total value of $75,018.06. Following the purchase, the director directly owned 2,703 shares of the company’s stock, valued at $1,733,109.54. This trade represents a 4.52% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Daniel Skovronsky purchased 1,000 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was bought at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the transaction, the executive vice president directly owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have bought 4,314 shares of company stock valued at $2,766,929. 0.14% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $938.13 on Friday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The company has a market cap of $886.89 billion, a P/E ratio of 61.32, a P/E/G ratio of 1.21 and a beta of 0.43. The stock has a 50-day moving average of $796.15 and a two-hundred day moving average of $775.03. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $955.46.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same quarter last year, the firm posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on LLY. DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Daiwa Capital Markets downgraded Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price for the company. in a research note on Sunday, August 17th. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Finally, Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $950.00.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.